RxDoctor Payments Data

Star Tangyie-Cheniba, NP

Psychiatric/Mental Health · Columbia, MDNPI 1679835698

Payments from drug & device makers

$754in general payments, 2019–2025

Across 20 payments — averaging $37.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$252
  • Axsome Therapeutics, Inc.$164
  • Otsuka America Pharmaceutical, Inc.$110
  • E.r. Squibb & Sons, L.L.C.$79
  • Vanda Pharmaceuticals Inc.$74
  • Johnson & Johnson$32
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$72696%
  • Education$284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$754 in reported general payments places this provider in the 65th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$73,010
Medicare patients
205
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate37$124,503
RexultiBrexpiprazole60$38,896
Abilify MaintenaAripiprazole12$35,555
Lurasidone Hcl27$19,539
Aripiprazole153$16,101
VraylarCariprazine Hcl11$15,048
Paliperidone ErPaliperidone29$7,725
Fluphenazine Hcl57$6,979
Clozapine100$6,623
Bupropion XlBupropion Hcl167$5,980
Divalproex Sodium ErDivalproex Sodium120$5,463
Olanzapine218$4,684
Fluvoxamine Maleate ErFluvoxamine Maleate12$4,418
Haloperidol156$4,106
Fluphenazine Decanoate32$4,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$32$124,50337 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$110$74,45172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →